Korean J Med.
2008 Feb;74(2):176-180.
Intravenous Anti-D immunoglobulin treatment of adult chronic immune thrombocytopenic purpura (ITP)
- Affiliations
-
- 1Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea. seog@e-bohun.or.kr
- 2Department of Internal Medicine, Bundang Cha Hospital, College of Medicine, Pochon Cha University, Bundang, Korea.
- 3Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Abstract
-
BACKGROUND/AIMS: Immune thrombocytopenic purpura (ITP) is an autoimmune disease that is mediated by anti-platelet antibodies. Based on the pathogenesis of ITP we evaluated the efficacy of intravenous anti-D immunoglobulin for adult chronic ITP.
METHODS
Fourteen patients (4 without splenectomy and 10 with splenectomy) with refractory chronic ITP were treated with 50-70 microgram/kg of intravenous anti-D immunoglobulin only once. Treatment effects were evaluated by measuring the platelet counts and hemoglobin levels.
RESULTS
Five patients (36%) showed a response; improvement in the platelet count lasted for on average 7 days (range: 2~24 days). There were no serious adverse effects.
CONCLUSION
Anti-D immunoglobulin, which is associated with an Fc receptor blockade, appeared to be safe and effective for the treatment of adults with chronic ITP. Further studies are needed to confirm these findings and define further potentially effective treatment protocols with intravenous anti-D immunoglobulin.